NXPL · NextPlat Corp
$9.68
+0.42 (+4.54%)
At close · Aug 31
Going-concern doubt
— cleared Aug 14, 2026
The latest filing states the doubt was alleviated.
“The Company has incurred recurring operating losses and historically generated negative operating cash flows. These conditions raised substantial doubt about the Company's ability to continue as a going concern for the twelve months following the issuance of these Condensed Consolidated Financial Statements. ... Based on these results, management's projections of operating results and cash flows for the twelve months following issuance, and the Company's liquidity position, management has concluded that its plans, which are probable of being effectively implemented and probable of mitigating the relevant conditions, alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$25.12M
Shares
2.71M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$54.32M
-17.8%
FY2025
Net Income
-$10.46M
+25.4%
FY2025
Gross Margin
20.08%
-5.7pp
FY2025
Operating Margin
-16.57%
+18.3pp
FY2025
Diluted EPS
-$4.40
+32.3%
FY2025
Operating Cash Flow
-$6.13M
-12.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $48.89M | $54.32M | $66.08MG | $37.76M | $11.71M | $7.74M | $5.69M | $5.87M | $5.73M | $6M | $4.7M | $3.95M | — | — | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | $6069 | — | -$120.58K | -$127.48K | -$658.16K | -$439.79K | |
| $35.63M | $43.42M | $49.07M | $26.45M | $9.22M | $5.88M | $4.46M | $4.65M | $4.69M | $4.85M | $3.62M | $2.97M | $1.74M | — | — | — | — | |
| $13.27M | $10.91M | $17.01M | $11.31M | $2.49M | $1.86M | $1.23M | $1.22M | $1.03M | $1.15M | $1.08M | $984.48K | $681.26K | — | — | — | — | |
| — | 20.08% | 25.74% | 29.96% | 21.26% | 24.03% | 21.54% | 20.84% | 18.07% | 19.16% | 22.88% | 24.92% | — | — | — | — | — | |
| $0 | — | — | — | — | $0 | $0 | — | $0 | $0 | $0 | $50K | $0 | — | — | — | — | |
| $800.92K | — | — | — | — | — | — | — | — | — | — | $644.87K | $401.11K | $573.79K | $98.55K | $341.23K | $333.61K | |
| $6.48M | $6.04M | $6.18M | $9.91M | $5.09M | $5.13M | $694.36K | $761.24K | $664.82K | $583.9K | $566.19K | $517.27K | — | — | — | — | — | |
| $102K | $102K | $1.71M | $1.34M | $25K | $25K | $25K | $25K | $25K | $25K | $25K | $25K | — | — | — | — | $381 | |
| — | $540K | $788K | $2.11M | $490K | $317.1K | $294.93K | $275.33K | $263.86K | $259.39K | $266.8K | $154K | $20.6K | — | — | — | — | |
| $19.58M | $19.91M | $40.03M | $34.54M | $9.69M | $8.48M | $3.26M | $2.33M | $2.16M | $2.71M | $2.71M | $2.98M | $667.44K | $573.79K | $4.67M | $1.94M | $4.29M | |
| -$6.32M | -$9M | -$23.03M | -$23.23M | -$7.2M | -$6.62M | -$2.03M | -$1.11M | -$1.13M | -$1.58M | -$1.63M | -$1.99M | $13.82K | -$573.79K | -$4.67M | -$1.94M | -$4.29M | |
| — | -16.57% | -34.84% | -61.52% | -61.51% | -85.56% | -35.75% | -18.93% | -19.73% | -26.27% | -34.7% | -50.41% | — | — | — | — | — | |
| — | -$8.46M | -$22.24M | -$21.12M | -$6.71M | -$6.31M | -$1.74M | -$836K | -$865.77K | -$1.32M | -$1.36M | -$1.84M | $34.42K | — | — | — | — | |
| — | $64K | $81K | $79K | $24K | — | — | — | — | — | — | — | — | $33.27K | $119.15K | — | — | |
| — | $358K | $731K | $620K | $21K | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$1.68M | -$1.46M | $570K | $937K | -$132K | -$1.49M | -$729.5K | $267.68K | $56.54K | $2.36M | $959.4K | $72.89K | $7325 | $1.2M | -$140.87K | -$6.78M | -$6.19M | |
| — | — | $0 | -$1.44M | -$1.74M | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$8M | -$10.46M | -$22.46M | -$12.38M | -$9.07M | -$8.11M | -$2.76M | -$1.38M | -$1.19M | -$3.92M | -$2.59M | -$2.06M | $6490 | $624.12K | -$4.81M | -$8.72M | -$10.48M | |
| $8000 | $0 | $71K | $28K | $87K | — | — | $747 | $8534 | $23.46K | — | — | — | — | — | — | — | |
| $2.46M | -$10.46M | -$14.03M | -$3.78M | -$9.16M | -$8.11M | -$2.76M | -$1.38M | -$1.19M | -$3.94M | -$2.59M | -$2.06M | $6490 | $624.12K | -$4.81M | -$8.72M | -$11.58M | |
| — | -19.26% | -21.22% | -10.01% | -78.23% | -104.75% | -48.57% | -23.51% | -20.86% | -65.6% | -55.12% | -52.25% | — | — | — | — | — | |
| -$14K | $0 | -$9.1M | -$8.63M | $0 | — | — | — | — | — | — | — | — | — | $4.8M | — | — | |
| -$9.24M | -$11.71M | -$13.43M | -$3.78M | -$9.16M | — | -$2.76M | -$1.18M | — | -$3.91M | -$2.61M | -$2.08M | $5641 | $624.12K | — | — | — | |
| -$7.97M | -$10.52M | -$22.53M | -$12.43M | -$9.2M | -$8.06M | -$2.8M | -$1.38M | -$1.2M | -$3.91M | — | — | — | — | — | — | — | |
| USD/shares | -$3.43 | -$4.40 | -$6.50 | -$2.20 | -$9.60 | -$19.80 | — | — | — | -$81.00 | -$114.20 | -$2.60 | $0.00 | $3.80 | — | — | — |
| USD/shares | — | -$4.40 | -$6.50 | -$2.20 | -$9.60 | — | — | — | — | -$81.00 | -$114.20 | -$2.60 | $0.00 | $3.60 | — | — | — |
| shares | — | 2.65M | 2.06M | 1.75M | 959.2K | 408.08K | 2123.5 | 10.62K | 6243.5 | 48.25K | 22.85K | 799.41K | 254K | 166.13K | 24.93M | 22.01M | — |
| shares | — | 2.65M | 2.06M | 1.75M | 959.2K | 408.08K | 2123.5 | 10.62K | 6243.5 | 48.25K | 22.85K | 799.41K | 9M | 171.46K | 24.93M | 22.01M | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2025: $100K in buybacks, $133.27K in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
0.29×
Peer median 1.10×
EV/EBIT
—
Peer median 33.74×
P/E (TTM)
—
Peer medians compare against the 72 similar-size Software - Application companies (of 198 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Healthcare Operations | $39,714,000 | $52,291,000 | $26,779,000 | $0 |
| Ecommerce | $14,608,000 | $13,791,000 | $10,977,000 | $11,710,000 |
| Ecommerce Revenue | $14,608,000 | $13,791,000 | $10,977,000 | $11,710,000 |
By Geography (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Europe | $5,146,336 | $3,658,612 |
| North America | $1,776,288 | $1,532,273 |
| Asia Pacific | $695,770 | $420,048 |
| Africa | $84,377 | $43,948 |
| South America | $37,139 | $34,915 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Pharmacy Prescription and Other Revenue Net of PBM Fees | $35,704,000 | $41,907,000 | $21,412,000 | $0 |
| Ecommerce Revenue | $14,608,000 | $13,791,000 | $10,977,000 | $11,710,000 |
| Pharmacy 340B Contract | $4,010,000 | $10,384,000 | $5,367,000 | $0 |
| Ecommerce | — | $13,791,000 | $10,977,000 | $11,710,000 |
| Pharmacy Prescription Other Revenue and Ecommerce | — | $55,099,000 | $32,389,000 | $11,710,000 |
| Product | — | $55,540,000 | $32,389,000 | $11,710,000 |
| Service | — | $10,542,000 | $5,367,000 | $0 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Ecommerce | -$4,396,000 | -$6,510,000 | -$8,690,000 | -$7,203,000 |
| Healthcare Operations | -$4,604,000 | -$16,755,000 | -$14,658,000 | $0 |
Operating Margin by Segment (%)
| Component | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Healthcare Operations | -11.6% | -32% | -54.7% | — |
| Ecommerce | -30.1% | -47.2% | -79.2% | -61.5% |